Switch to:
Also traded in: Argentina, Germany, Mexico, Switzerland, UK, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.28
NVS's Cash-to-Debt is ranked lower than
80% of the 799 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.05 vs. NVS: 0.28 )
Ranked among companies with meaningful Cash-to-Debt only.
NVS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.18  Med: 1.15 Max: N/A
Current: 0.28
Equity-to-Asset 0.52
NVS's Equity-to-Asset is ranked lower than
68% of the 731 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. NVS: 0.52 )
Ranked among companies with meaningful Equity-to-Asset only.
NVS' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.51  Med: 0.58 Max: 0.65
Current: 0.52
0.51
0.65
Interest Coverage 11.07
NVS's Interest Coverage is ranked lower than
72% of the 632 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 112.31 vs. NVS: 11.07 )
Ranked among companies with meaningful Interest Coverage only.
NVS' s Interest Coverage Range Over the Past 10 Years
Min: 11.07  Med: 16.22 Max: 30.91
Current: 11.07
11.07
30.91
Piotroski F-Score: 6
Altman Z-Score: 2.44
Beneish M-Score: -2.80
WACC vs ROIC
6.05%
7.38%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 16.05
NVS's Operating Margin % is ranked higher than
72% of the 758 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.95 vs. NVS: 16.05 )
Ranked among companies with meaningful Operating Margin % only.
NVS' s Operating Margin % Range Over the Past 10 Years
Min: 16.05  Med: 20.76 Max: 22.35
Current: 16.05
16.05
22.35
Net Margin % 13.23
NVS's Net Margin % is ranked higher than
72% of the 759 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.06 vs. NVS: 13.23 )
Ranked among companies with meaningful Net Margin % only.
NVS' s Net Margin % Range Over the Past 10 Years
Min: 13.23  Med: 18.81 Max: 35.29
Current: 13.23
13.23
35.29
ROE % 9.09
NVS's ROE % is ranked higher than
56% of the 780 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.91 vs. NVS: 9.09 )
Ranked among companies with meaningful ROE % only.
NVS' s ROE % Range Over the Past 10 Years
Min: 8.95  Med: 14.79 Max: 25.73
Current: 9.09
8.95
25.73
ROA % 4.94
NVS's ROA % is ranked higher than
56% of the 805 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.71 vs. NVS: 4.94 )
Ranked among companies with meaningful ROA % only.
NVS' s ROA % Range Over the Past 10 Years
Min: 4.94  Med: 8.59 Max: 16.19
Current: 4.94
4.94
16.19
ROC (Joel Greenblatt) % 49.37
NVS's ROC (Joel Greenblatt) % is ranked higher than
82% of the 793 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 13.48 vs. NVS: 49.37 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NVS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 43.78  Med: 59.62 Max: 69.75
Current: 49.37
43.78
69.75
3-Year Revenue Growth Rate 2.90
NVS's 3-Year Revenue Growth Rate is ranked lower than
58% of the 634 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.10 vs. NVS: 2.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NVS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -3.9  Med: 2.5 Max: 12.3
Current: 2.9
-3.9
12.3
3-Year EBITDA Growth Rate -4.80
NVS's 3-Year EBITDA Growth Rate is ranked lower than
74% of the 601 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.90 vs. NVS: -4.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NVS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -7.7  Med: 0.4 Max: 11.6
Current: -4.8
-7.7
11.6
3-Year EPS without NRI Growth Rate -4.80
NVS's 3-Year EPS without NRI Growth Rate is ranked lower than
67% of the 576 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.60 vs. NVS: -4.80 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NVS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -7.1  Med: 3.2 Max: 82
Current: -4.8
-7.1
82
GuruFocus has detected 6 Warning Signs with Novartis AG $NVS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NVS's 30-Y Financials

Financials (Next Earnings Date: 2017-10-18 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

NVS Guru Trades in Q3 2016

Mairs and Power 6,354 sh (+68.10%)
Jim Simons 2,515,098 sh (+11.26%)
Manning & Napier Advisors, Inc 3,752,105 sh (+5.26%)
Mario Gabelli 6,265 sh (+4.16%)
Sarah Ketterer 321,258 sh (+0.60%)
First Eagle Investment 12,848 sh (unchged)
Kahn Brothers 27,643 sh (unchged)
Tom Gayner 3,700 sh (unchged)
Murray Stahl 29,250 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund 255,700 sh (unchged)
PRIMECAP Management 20,557,433 sh (-1.32%)
Dodge & Cox 43,581,886 sh (-1.77%)
Ken Fisher 6,065,150 sh (-4.69%)
Tweedy Browne 220,115 sh (-5.85%)
John Rogers 13,914 sh (-6.10%)
» More
Q4 2016

NVS Guru Trades in Q4 2016

Chris Davis 257,670 sh (New)
Manning & Napier Advisors, Inc 5,554,008 sh (+48.02%)
John Rogers 15,402 sh (+10.69%)
Dodge & Cox 45,718,521 sh (+4.90%)
PRIMECAP Management 21,246,828 sh (+3.35%)
Ken Fisher 6,074,870 sh (+0.16%)
First Eagle Investment 12,848 sh (unchged)
Tom Gayner 3,700 sh (unchged)
Sarah Ketterer 318,018 sh (-1.01%)
Tweedy Browne 216,590 sh (-1.60%)
Kahn Brothers 27,071 sh (-2.07%)
Mairs and Power 6,053 sh (-4.74%)
Mario Gabelli 5,870 sh (-6.30%)
Jim Simons 2,287,000 sh (-9.07%)
Murray Stahl 24,850 sh (-15.04%)
Eaton Vance Worldwide Health Sciences Fund 172,411 sh (-32.57%)
» More
Q1 2017

NVS Guru Trades in Q1 2017

Steven Cohen 670,600 sh (New)
Jerome Dodson 285,000 sh (New)
John Rogers 48,737 sh (+216.43%)
Chris Davis 298,710 sh (+15.93%)
Dodge & Cox 50,585,790 sh (+10.65%)
Jim Simons 2,458,498 sh (+7.50%)
Sarah Ketterer 338,149 sh (+6.33%)
Kahn Brothers 27,911 sh (+3.10%)
PRIMECAP Management 21,693,804 sh (+2.10%)
Ken Fisher 6,121,673 sh (+0.77%)
First Eagle Investment 12,848 sh (unchged)
Tom Gayner 3,700 sh (unchged)
Murray Stahl 24,850 sh (unchged)
Mairs and Power 5,894 sh (-2.63%)
Mario Gabelli 5,620 sh (-4.26%)
Tweedy Browne 204,747 sh (-5.47%)
Manning & Napier Advisors, Inc 5,002,121 sh (-9.94%)
Eaton Vance Worldwide Health Sciences Fund 93,506 sh (-45.77%)
» More
Q2 2017

NVS Guru Trades in Q2 2017

Pioneer Investments 96,500 sh (New)
Chris Davis 352,820 sh (+18.11%)
Sarah Ketterer 369,006 sh (+9.13%)
Murray Stahl 27,040 sh (+8.81%)
Ken Fisher 6,505,935 sh (+6.28%)
John Rogers 49,665 sh (+1.90%)
PRIMECAP Management 22,094,224 sh (+1.85%)
Jerome Dodson 285,000 sh (unchged)
Tom Gayner 3,700 sh (unchged)
First Eagle Investment 12,848 sh (unchged)
Eaton Vance Worldwide Health Sciences Fund Sold Out
Dodge & Cox 50,143,509 sh (-0.87%)
Mario Gabelli 5,495 sh (-2.22%)
Tweedy Browne 196,422 sh (-4.07%)
Manning & Napier Advisors, Inc 4,767,723 sh (-4.69%)
Kahn Brothers 26,211 sh (-6.09%)
Mairs and Power 4,250 sh (-27.89%)
Jim Simons 1,474,500 sh (-40.02%)
Steven Cohen 115,900 sh (-82.72%)
» More
» Details

Insider Trades

Latest Guru Trades with NVS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Dodge & Cox 2017-06-30 Reduce -0.87%0.03%$72.74 - $86.34 $ 84.377%50,143,509
Ken Fisher 2017-06-30 Add 6.28%0.05%$72.74 - $86.34 $ 84.377%6,505,935
Chris Davis 2017-06-30 Add 18.11%0.02%$72.74 - $86.34 $ 84.377%352,820
Tweedy Browne 2017-06-30 Reduce -4.07%0.02%$72.74 - $86.34 $ 84.377%196,422
John Rogers 2017-06-30 Add 1.90%$72.74 - $86.34 $ 84.377%49,665
Kahn Brothers 2017-06-30 Reduce -6.09%0.02%$72.74 - $86.34 $ 84.377%26,211
Mario Gabelli 2017-06-30 Reduce -2.22%$72.74 - $86.34 $ 84.377%5,495
Dodge & Cox 2017-03-31 Add 10.65%0.31%$70.03 - $78.17 $ 84.3713%50,585,790
Ken Fisher 2017-03-31 Add 0.77%0.01%$70.03 - $78.17 $ 84.3713%6,121,673
Chris Davis 2017-03-31 Add 15.93%0.01%$70.03 - $78.17 $ 84.3713%298,710
Tweedy Browne 2017-03-31 Reduce -5.47%0.03%$70.03 - $78.17 $ 84.3713%204,747
John Rogers 2017-03-31 Add 216.43%0.03%$70.03 - $78.17 $ 84.3713%48,737
Kahn Brothers 2017-03-31 Add 3.10%0.01%$70.03 - $78.17 $ 84.3713%27,911
Mario Gabelli 2017-03-31 Reduce -4.26%$70.03 - $78.17 $ 84.3713%5,620
Dodge & Cox 2016-12-31 Add 4.90%0.14%$67.59 - $79.13 $ 84.3717%45,718,521
Ken Fisher 2016-12-31 Add 0.16%$67.59 - $79.13 $ 84.3717%6,074,870
Chris Davis 2016-12-31 New Buy0.08%$67.59 - $79.13 $ 84.3717%257,670
Tweedy Browne 2016-12-31 Reduce -1.60%0.01%$67.59 - $79.13 $ 84.3717%216,590
Kahn Brothers 2016-12-31 Reduce -2.07%0.01%$67.59 - $79.13 $ 84.3717%27,071
John Rogers 2016-12-31 Add 10.69%$67.59 - $79.13 $ 84.3717%15,402
Mario Gabelli 2016-12-31 Reduce -6.30%$67.59 - $79.13 $ 84.3717%5,870
Dodge & Cox 2016-09-30 Reduce -1.77%0.06%$78.27 - $83.51 $ 84.374%43,581,886
Ken Fisher 2016-09-30 Reduce -4.69%0.05%$78.27 - $83.51 $ 84.374%6,065,150
Tweedy Browne 2016-09-30 Reduce -5.85%0.03%$78.27 - $83.51 $ 84.374%220,115
John Rogers 2016-09-30 Reduce -6.10%$78.27 - $83.51 $ 84.374%13,914
Mario Gabelli 2016-09-30 Add 4.16%$78.27 - $83.51 $ 84.374%6,265
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major    NAICS: 325412 
Compare:XSWX:RO » details
Traded in other countries:NVS.Argentina, NOT.Germany, NVS N.Mexico, NOVN.Switzerland, 0HKE.UK, NVSEF.USA,
Headquarter Location:Switzerland
Novartis AG is a part of the healthcare industry. Its main activity is to research and develop healthcare products and pharmaceuticals such as oncology medicines, generic and biosimilar medicines and eye care devices.

Novartis develops and manufactures healthcare products within four main operating segments: branded drugs, generic pharmaceuticals, eye care products, and consumer products. The company sells its products globally with the U.S. representing close to a third of total sales.

Guru Investment Theses on Novartis AG

Jerome Dodson Comments on Novartis - Apr 26, 2017

With the market at all-time highs, it’s difficult to find undervalued stocks with attractive prospects. However, we uncovered a few that we believe are hidden gems. Our first new addition is Novartis (NYSE:NVS), the Swiss pharmaceutical giant. Management is focused on turning around Alcon, its leading eye-care franchise, whose sales have been soft the past few years. We recently met with Mike Ball, the CEO of Alcon, and we’re impressed with his vision to reinvigorate this great business. Meanwhile, investors are giving the company little credit for its enviable portfolio of innovative therapies that should drive revenue growth, including Entresto, an exciting new treatment that provides hope for chronic heart failure patients.

Jerome Dodson (Trades, Portfolio)'s first quarter 2017 Parnassus Funds commentary.

Check out Jerome Dodson latest stock trades

Top Ranked Articles about Novartis AG

Why Emmaus Might Have Just Made Itself Attractive to Big Pharma How the company's latest development makes it a potential takeover target
If you would have mentioned the name Emmaus Life Sciences to an investor, even one familiar with the biotechnology space, a couple of months ago, chances are the said investor would not have had any idea who you were talking about. In fact, the same probably applies today. Read more...
DURECT's Collaboration with Sandoz Clears HSR Review and is Effective
Spring Bank Pharmaceuticals' Hepatitis B Results in Context Here's a look at where the company's latest data fit into the hepatitis B space as a whole
Spring Bank Pharmaceuticals Inc. (NASDAQ:SBPH) announced positive initial Phase II results for its new antiviral hepatitis B (HBV) treatment SB-9200. Shares have recorded all-time highs, up as much as 28% on the news. Read more...
Dodge & Cox Buys Express Scripts, Bristol-Myers, HP The guru's largest 1st-quarter transactions
Dodge & Cox was founded in 1930 by Van Duyn Dodge and E. Morris Cox, and it manages a portfolio of 179 stocks. During the first quarter the guru traded shares in the following companies. Read more...
DURECT and Sandoz have Signed a $293 Million Development and Commercialization Agreement for POSIMIR® (SABER®-Bupivacaine) Covering the United States
Novartis Releases 1st-Quarter Earnings The Swiss company reported a solid quarter with a substantial increase in cash flow
Novartis AG (NYSE:NVSreleased its first-quarter 2017 financial results on April 25.  Read more...
Jerome Dodson Comments on Novartis Guru stock highlight
With the market at all-time highs, it’s difficult to find undervalued stocks with attractive prospects. However, we uncovered a few that we believe are hidden gems. Our first new addition is Novartis (NYSE:NVS), the Swiss pharmaceutical giant. Management is focused on turning around Alcon, its leading eye-care franchise, whose sales have been soft the past few years. We recently met with Mike Ball, the CEO of Alcon, and we’re impressed with his vision to reinvigorate this great business. Meanwhile, investors are giving the company little credit for its enviable portfolio of innovative therapies that should drive revenue growth, including Entresto, an exciting new treatment that provides hope for chronic heart failure patients. Read more...
Jerome Dodson Buys 2 Stocks, Sells 2 in 1st Quarter Guru invests in IT and pharmaceutical companies
Jerome Dodson (Trades, Portfolio)’s Parnassus Fund established two new positions and sold out of two others in the first quarter of the year. He bought Cognizant Technology Solutions Corp. (NASDAQ:CTSH) and Novartis AG (NYSE:NVS). He sold Qualcomm Inc. (NASDAQ:QCOM) and Applied Materials Inc. (NASDAQ:AMAT). Read more...
Gilead’s Patience Is Wearing Investors' Patience Thin Despite sitting on a cash pile, the company has been slow in the acquisitions space
Gilead’s (NASDAQ:GILD) stock price has been on a never-ending slide since the second half of last year. The stock is now trading at less than 7 times earnings after dropping more than a quarter of its valuation in the last twelve months. But a key question that remains after analyzing Gilead is why the company is sitting on its cash pile without doing anything. Read more...
Novartis Is Surviving Restructuring leads to promising future business developments
On July 19, the $188 billion Swiss multinational pharmaceutical company delivered its first half fiscal year 2016 results. The company delivered constant currency sales and profit growth of 1% to $24 billion and -2% to $3.8 billion, respectively. Novartis (NYSE:NVS) shares closed -0.62% that day, while the broader S&P 500 index closed -0.14%. Read more...

Ratios

vs
industry
vs
history
PE Ratio 30.28
NVS's PE Ratio is ranked lower than
55% of the 555 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 26.93 vs. NVS: 30.28 )
Ranked among companies with meaningful PE Ratio only.
NVS' s PE Ratio Range Over the Past 10 Years
Min: 5.7  Med: 15.92 Max: 30.99
Current: 30.28
5.7
30.99
Forward PE Ratio 17.76
NVS's Forward PE Ratio is ranked higher than
58% of the 67 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 18.90 vs. NVS: 17.76 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 30.28
NVS's PE Ratio without NRI is ranked lower than
55% of the 554 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.21 vs. NVS: 30.28 )
Ranked among companies with meaningful PE Ratio without NRI only.
NVS' s PE Ratio without NRI Range Over the Past 10 Years
Min: 10.63  Med: 18.23 Max: 31.15
Current: 30.28
10.63
31.15
Price-to-Owner-Earnings 20.31
NVS's Price-to-Owner-Earnings is ranked higher than
71% of the 303 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 32.90 vs. NVS: 20.31 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
NVS' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 7.18  Med: 15.39 Max: 21.91
Current: 20.31
7.18
21.91
PB Ratio 2.83
NVS's PB Ratio is ranked higher than
50% of the 751 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.80 vs. NVS: 2.83 )
Ranked among companies with meaningful PB Ratio only.
NVS' s PB Ratio Range Over the Past 10 Years
Min: 1.69  Med: 2.44 Max: 3.74
Current: 2.83
1.69
3.74
PS Ratio 4.01
NVS's PS Ratio is ranked lower than
59% of the 736 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.97 vs. NVS: 4.01 )
Ranked among companies with meaningful PS Ratio only.
NVS' s PS Ratio Range Over the Past 10 Years
Min: 1.89  Med: 3.26 Max: 5.03
Current: 4.01
1.89
5.03
Price-to-Free-Cash-Flow 20.50
NVS's Price-to-Free-Cash-Flow is ranked higher than
60% of the 208 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 25.89 vs. NVS: 20.50 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
NVS' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 7.04  Med: 17.14 Max: 26.65
Current: 20.5
7.04
26.65
Price-to-Operating-Cash-Flow 15.85
NVS's Price-to-Operating-Cash-Flow is ranked higher than
57% of the 277 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 19.02 vs. NVS: 15.85 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
NVS' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 5.75  Med: 13.23 Max: 19.28
Current: 15.85
5.75
19.28
EV-to-EBIT 25.93
NVS's EV-to-EBIT is ranked lower than
64% of the 559 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 20.11 vs. NVS: 25.93 )
Ranked among companies with meaningful EV-to-EBIT only.
NVS' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.5  Med: 15.6 Max: 27
Current: 25.93
8.5
27
EV-to-EBITDA 16.68
NVS's EV-to-EBITDA is ranked higher than
52% of the 587 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 17.50 vs. NVS: 16.68 )
Ranked among companies with meaningful EV-to-EBITDA only.
NVS' s EV-to-EBITDA Range Over the Past 10 Years
Min: 7.3  Med: 12.2 Max: 18.1
Current: 16.68
7.3
18.1
Shiller PE Ratio 17.09
NVS's Shiller PE Ratio is ranked higher than
87% of the 198 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 39.37 vs. NVS: 17.09 )
Ranked among companies with meaningful Shiller PE Ratio only.
NVS' s Shiller PE Ratio Range Over the Past 10 Years
Min: 9.73  Med: 14.96 Max: 21.48
Current: 17.09
9.73
21.48
Current Ratio 1.01
NVS's Current Ratio is ranked lower than
89% of the 782 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.40 vs. NVS: 1.01 )
Ranked among companies with meaningful Current Ratio only.
NVS' s Current Ratio Range Over the Past 10 Years
Min: 0.83  Med: 1.32 Max: 2.83
Current: 1.01
0.83
2.83
Quick Ratio 0.75
NVS's Quick Ratio is ranked lower than
88% of the 782 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.82 vs. NVS: 0.75 )
Ranked among companies with meaningful Quick Ratio only.
NVS' s Quick Ratio Range Over the Past 10 Years
Min: 0.59  Med: 1.04 Max: 2.48
Current: 0.75
0.59
2.48
Days Inventory 139.97
NVS's Days Inventory is ranked lower than
60% of the 707 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 117.36 vs. NVS: 139.97 )
Ranked among companies with meaningful Days Inventory only.
NVS' s Days Inventory Range Over the Past 10 Years
Min: 117.82  Med: 150.76 Max: 183.45
Current: 139.97
117.82
183.45
Days Sales Outstanding 60.73
NVS's Days Sales Outstanding is ranked higher than
63% of the 651 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 74.70 vs. NVS: 60.73 )
Ranked among companies with meaningful Days Sales Outstanding only.
NVS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 56.31  Med: 63.6 Max: 70.59
Current: 60.73
56.31
70.59
Days Payable 97.16
NVS's Days Payable is ranked higher than
67% of the 600 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 70.96 vs. NVS: 97.16 )
Ranked among companies with meaningful Days Payable only.
NVS' s Days Payable Range Over the Past 10 Years
Min: 95.93  Med: 116.45 Max: 135.35
Current: 97.16
95.93
135.35

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 3.22
NVS's Dividend Yield % is ranked higher than
91% of the 691 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.23 vs. NVS: 3.22 )
Ranked among companies with meaningful Dividend Yield % only.
NVS' s Dividend Yield % Range Over the Past 10 Years
Min: 1.49  Med: 3.43 Max: 5.11
Current: 3.22
1.49
5.11
Dividend Payout Ratio 0.99
NVS's Dividend Payout Ratio is ranked lower than
92% of the 406 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.33 vs. NVS: 0.99 )
Ranked among companies with meaningful Dividend Payout Ratio only.
NVS' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.4  Med: 0.64 Max: 0.99
Current: 0.99
0.4
0.99
3-Year Dividend Growth Rate 7.60
NVS's 3-Year Dividend Growth Rate is ranked higher than
52% of the 299 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.90 vs. NVS: 7.60 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
NVS' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -70.6  Med: 7.85 Max: 18.5
Current: 7.6
-70.6
18.5
Forward Dividend Yield % 3.23
NVS's Forward Dividend Yield % is ranked higher than
83% of the 673 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. NVS: 3.23 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 4.15
NVS's 5-Year Yield-on-Cost % is ranked higher than
88% of the 821 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.11 vs. NVS: 4.15 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
NVS' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 1.92  Med: 4.42 Max: 6.58
Current: 4.15
1.92
6.58
3-Year Average Share Buyback Ratio 0.70
NVS's 3-Year Average Share Buyback Ratio is ranked higher than
91% of the 473 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.10 vs. NVS: 0.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
NVS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -2.1  Med: 1.05 Max: 2.4
Current: 0.7
-2.1
2.4

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 28.89
NVS's Price-to-Tangible-Book is ranked lower than
97% of the 690 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.51 vs. NVS: 28.89 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
NVS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.68  Med: 4.43 Max: 12455
Current: 28.89
2.68
12455
Price-to-Intrinsic-Value-Projected-FCF 1.34
NVS's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
73% of the 328 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.31 vs. NVS: 1.34 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
NVS' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.67  Med: 1.16 Max: 2.52
Current: 1.34
0.67
2.52
Price-to-Median-PS-Value 1.23
NVS's Price-to-Median-PS-Value is ranked lower than
58% of the 712 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.09 vs. NVS: 1.23 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
NVS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.64  Med: 1.15 Max: 3.11
Current: 1.23
0.64
3.11
Price-to-Graham-Number 6.24
NVS's Price-to-Graham-Number is ranked lower than
93% of the 480 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.08 vs. NVS: 6.24 )
Ranked among companies with meaningful Price-to-Graham-Number only.
NVS' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.27  Med: 2.07 Max: 81.67
Current: 6.24
1.27
81.67
Earnings Yield (Greenblatt) % 3.86
NVS's Earnings Yield (Greenblatt) % is ranked higher than
55% of the 805 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. NVS: 3.86 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
NVS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 3.7  Med: 6.4 Max: 11.8
Current: 3.86
3.7
11.8
Forward Rate of Return (Yacktman) % 2.93
NVS's Forward Rate of Return (Yacktman) % is ranked lower than
64% of the 380 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.46 vs. NVS: 2.93 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
NVS' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 1  Med: 12.8 Max: 50.1
Current: 2.93
1
50.1

More Statistics

Revenue (TTM) (Mil) $49,226.00
EPS (TTM) $ 2.74
Beta0.70
Short Percentage of Float0.00%
52-Week Range $66.93 - 86.90
Shares Outstanding (Mil)2,342.90 (ADR)

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 49,136 51,093 54,691
EPS ($) 4.77 5.20 5.74
EPS without NRI ($) 4.77 5.20 5.74
EPS Growth Rate
(Future 3Y To 5Y Estimate)
3.80%
Dividends per Share ($) 2.82 2.95 3.18
» More Articles for NVS

Headlines

Articles On GuruFocus.com
AstraZeneca’s Other Pharmaceutical Products Need to Catch Up Aug 03 2017 
The World's Largest Generic Drugmaker Is Plunging Jul 19 2017 
Why Emmaus Might Have Just Made Itself Attractive to Big Pharma Jul 14 2017 
DURECT's Collaboration with Sandoz Clears HSR Review and is Effective Jun 19 2017 
Spring Bank Pharmaceuticals' Hepatitis B Results in Context Jun 07 2017 
Dodge & Cox Buys Express Scripts, Bristol-Myers, HP May 25 2017 
DURECT and Sandoz have Signed a $293 Million Development and Commercialization Agreement for POSIMIR May 08 2017 
Jerome Dodson Comments on Novartis Apr 26 2017 
Novartis Releases 1st-Quarter Earnings Apr 26 2017 
Jerome Dodson Buys 2 Stocks, Sells 2 in 1st Quarter Apr 17 2017 

More From Other Websites
Ophthotech's Fovista Combo Regimen Disappoints in Phase III Aug 16 2017
CYRX: Raising Price Target on CAR-T Opportunity Aug 16 2017
Pfizer’s Important Product Developments in 2Q17 Aug 15 2017
3 Stocks to Buy With Dividends Yielding More Than 3% Aug 14 2017
Luspatercept: Opportunity for Celgene’s Long-Term Growth? Aug 11 2017
How Celgene Performed in 2Q17 Aug 09 2017
Why Vertex Pharmaceuticals Incorporated (VRTX) Will Keep Rolling Higher Aug 08 2017
Analysts say a United Therapeutics sale is premature Aug 04 2017
United Therapeutics Corporation (UTHR) Shares Soar on Takeover Talk Aug 04 2017
Gilead Could Be Making An Acquisition — But It's Not What You Think Aug 04 2017
ETFs with exposure to Novartis AG : August 4, 2017 Aug 03 2017
Conatus (CNAT) Q2 Loss Narrows Y/Y, Revenues Beat Estimates Aug 03 2017
Aduro (ADRO) Q2 Loss Narrower than Expected, Revenues Top Aug 03 2017
Momenta Pharmaceuticals, Inc. Treads Water in the Second Quarter Aug 03 2017
Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Stock Hits 13-Year Low Aug 03 2017
Moderna taps Novartis exec to lead manufacturing blitz Aug 03 2017
Drugmakers Hunt for Patients in India’s Remote Corners Aug 02 2017
GlaxoSmithKline’s 2Q17 Earnings: Vaccines Business Aug 02 2017
Pfizer on the Street: Inside the Analysts’ Recommendations Jul 28 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)